Advanced Accelerator Applications announces that it has officially opened a new office in the US. The office is in the heart of Manhattan in New York City.
This is an important step for AAA as the US is a key market for molecular nuclear medicine with nearly half of all nuclear medicine procedures worldwide taking place in the US. The aim is to accelerate the company’s international growth and further expand its presence and activities in the US as it is advancing in its phase III clinical trial for its lead product Lu-DOTATATE for the treatment of Gastro-Entero-Pancreatic Neuro Endocrine Tumors (GEP-NETs).
AAA’s New York office is located in the Empire State Building and will initially host a few employees, including the company’s CEO. The company aims to grow its East Coast-based team to up to thirty people in the next 2 years to support its clinical studies for Ga68-DOTATATE (Somakit) and Annexin. AAA’s New York office will also be heading all developments linked to the setting up of a new manufacturing facility in the US and the launch of AAA’s commercial activity in the US.